Covance Expands Analytical and Stability Service Capacity in North America

- Covance doubles service capacity to provide integrated discovery,
preclinical, and clinical development support for large-scale stability and
release programs -

PRINCETON, N.J., June 29 /PRNewswire/ -- Covance Inc. today announced the
expansion of the company's analytical and stability services facility in
Madison, Wisconsin. The expanded facility doubles service capacity for
large-scale, long-term stability and release programs supporting preclinical,
clinical, and chemistry, manufacturing, and control (CMC) development of
pharmaceutical and animal health products.

"Covance is committed to providing world-class CMC analytical services for our
clients to provide the highest quality data and reduce developments
timelines," said Henry Hummel, vice president and general manager, Madison
sites, Covance. "Together with our integrated discovery, preclinical, and
clinical service offerings and dedicated program management team, we can now
offer CMC analytical services as part of an entire molecule development
program."

The expanded facility includes upgraded stability chambers equipped with
high-density tracked shelving to significantly increase pharmaceutical
analysis service capacity and utilization. Designed to house up to ten
walk-in chambers and several reach-in chambers, the facility also provides
space to accommodate future expansion.

As a leading contract service provider to the global pharmaceutical and animal
health industry, Covance offers a comprehensive portfolio of CMC analytical
services, including analytical method development, validation and transfer,
stability, and product release testing. Covance also offers expertise in
inhalation, extractables and leachables, and nitrosamine testing.

About Covance
Covance, with headquarters in Princeton, New Jersey, is one of the world's
largest and most comprehensive drug development services companies with annual
revenues greater than $1.7 billion, global operations in more than 25
countries, and more than 9,800 employees worldwide. Information on Covance's
products and services, recent press releases, and SEC filings can be obtained
through its website at www.covance.com.

Statements contained in this press release, which are not historical facts,
are forward-looking statements pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All such forward-looking
statements including the statements contained herein regarding anticipated
trends in the Company's business are based largely on management's
expectations and are subject to an qualified by risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied by such statements. These risks and uncertainties include, without
limitation, competitive factors, outsourcing trends in the pharmaceutical
industry, levels of industry research and development spending, the Company's
ability to continue to attract and retain qualified personnel, the fixed price
nature of contracts or the loss of large contracts, and other factors
described in the Company's filings with the Securities and Exchange
Commission.

SOURCE Covance Inc.

Media Relations, +1-609-452-4275, or Investor Relations, +1-609-452-4807